Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Lung Cancer. 2014 Mar 29;85(1):1–6. doi: 10.1016/j.lungcan.2014.03.021

Figure 3.

Figure 3

Figure 3

A) Erlotinib alters the expression of SOX2 and OCT4 in EGFR mutant NSCLC cell lines. Immunoblot analysis of H1975 and HCC827 cells treated with varying doses of erlotinib for 3 and 9 days. C=vehicle control. B) PI3K/AKT pathway inhibitors decrease SOX2 expression in NSCLC cell lines. Immunoblot analysis of H1975 (left) and HCC827 (right) cells treated with DMSO (C), 10μM LY294002 (LY) or 10μM tricibine (T) for the indicated times.